7th September 2023
Neuigkeiten
Bleiben Sie auf dem neuesten Stand. Hier finden Sie unsere Pressemitteilungen. Hier können Sie sich über bevorstehende Veranstaltungen informieren, an denen Curium teilnehmen wird.
15th August 2023
Curium announces achievement of co-primary endpoints in phase 2 of its phase 1/2 SOLAR clinical trial imaging men with histologically-proven prostate cancer using copper Cu 64 PSMA I&T
28th Juli 2023
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
25th Juli 2023
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
21st Juli 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
21st Juli 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
26th Mai 2023
Curium receives positive CHMP opinion of PYLCLARI® for primary staging of patients with high-risk PCa prior to initial curative therapy and to localize recurrence of PCa in patients with a suspected recurrence based on increasing serum Prostate-Specific Antigen (PSA) levels after primary treatment with curative intent
23rd Mai 2023
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
2nd Mai 2023
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
14th März 2023
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
2nd März 2023
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
27th Januar 2023
Curium is attending these global congresses in 2023
21st Dezember 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th November 2022
Curium’s Customers to benefit from Mo-99 Production restart
22nd November 2022
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
9th November 2022
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
18th August 2022
NRG and Curium Sign Multi-Year Isotope Production Contract
27th Juni 2022
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
12th Mai 2022
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
3rd Mai 2022